Ottawa-based treatment an unprecedented leap forward in addressing damage after heart attack – Ottawa Citizen

Veronika Sedlakova, post-doctoral fellow (L), Sarah Mclaughlin, PhD(c), and Dr. Emilio Alarcon, principal investigator and laboratory director, University of Ottawa Heart Institute, have developed a recombinant human collagen matrix for cardiac tissue repair. October 24, 2019. Errol McGihon / Postmedia

It took years for Emilio Alarcon and his University of Ottawa Heart Institute research team to fully believe what they were seeing that a gel they had developed containing human collagen was repairing damaged hearts in mice.

They repeated their research study several times, coming up with randomized, blinded results, just to make sure the findings were correct.

We had to complete it many times because we couldnt believe it, he said.

The results of that work, five years in the making, were published in the prestigious journal Nature Communications on Friday. Alarcon and Erik Suuronen, a scientist in the division of cardiac surgery and director of its biomaterials and regeneration program, are lead authors.

The injectable material is the first in the world prepared using human collagen and is being called an unprecedented leap forward in addressing repair of cardiac muscle after a heart attack.

The work is still years away from clinical use on humans, but the findings are expected to attract attention because of the potential of the gel, which is designed to be injected into the hearts of patients with damaged heart tissue after a heart attack.

Alarcon said his team believes it performs better than any of the cell-based therapies or drug treatments currently available. The treatment works, he said, by increasing the number of cardiac muscle cells and blood capillaries in the tissue around damaged areas of the heart. The gel also helps bring more wound-healing cells to the site to promote repair.

Heart diseases are the leading cause of death around the world, and coronary artery disease, which can lead to a heart attack, is the most common.

About 10 per cent of people who have a heart attack (or myocardial infarction) will develop scarring and thickening of the heart wall that can lead to heart failure, which has a high mortality rate and its treatment is costly to the health system.

Alarcon noted that patients in remote areas without easy access to health care and those who dont seek immediate treatment or dont know they had a heart attack are more likely to suffer heart muscle damage. The treatment being developed by the heart institute team restored heart function in mice with scarred cardiac muscle.

The heart institutes BioEngineering and Therapeutic Solutions (BEaTS) team are hopeful their human collagen gel will one day lead to a recovery of heart function and prevent heart failure in humans, said Alarcon, but more testing is required.

The study published Friday is a first step toward that potential treatment, he said.

In Canada, approximately 600,000 patients live with advanced heart failure and health-care costs amount to more than $2.8 billion every year. As people live longer, both the number of patients and the cost of treatments are likely to increase.

ALSO IN THE NEWS

Mistake airline fares are the best way to score super cheap plane tickets. Heres how

Canadian scientists say they have produced the rarest drug on earth for cancer treatment

Fourth federal government office building treated for bedbugs

View post:

Ottawa-based treatment an unprecedented leap forward in addressing damage after heart attack - Ottawa Citizen